Licensing deal signed for listed company’s health product

York-based life sciences company Optibiotix Health says its wholly-owned subsidiary ProBiotix Health has signed a licencing agreement with Granja Pocha SA.

This is for the inclusion of ProBiotix’s patented probiotic strain LP_LDL® into a yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix’s cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP_LDL®, under a non-exclusive licence to Granja Pocha.

It will then be included in fermented milk products, such as yogurts, in Uruguay, to maximise the financial return for both Granja Pocha and ProBiotix.

Steve Prescott, CEO of ProBiotix, said: “We are pleased to announce this agreement with Granja Pocha, which will expand LP_LDL®’s presence into South America and extends its use into dairy products.

“Granja Pocha was chosen as our partner to create a functional yogurt containing LP_LDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.

“Functional foods like this yogurt containing ProBiotix’s LP_LDL® provide a unique format for customer to receive the cholesterol reducing benefits of LP_LDL® and capitalises on a growing industry trend towards functional foods.”